Holen Sie sich die Stockscreener-App
0.6233
0.91%
-0.0057
Handel nachbörslich:
.61
-0.0133
-2.13%
Schlusskurs vom Vortag:
$0.629
Offen:
$0.63
24-Stunden-Volumen:
236.46K
Relative Volume:
0.53
Marktkapitalisierung:
$13.30M
Einnahmen:
$1.89M
Nettoeinkommen (Verlust:
$-17.92M
KGV:
-0.0932
EPS:
-6.69
Netto-Cashflow:
$-15.62M
1W Leistung:
+5.11%
1M Leistung:
-4.11%
6M Leistung:
-58.45%
1J Leistung:
-65.56%
1-Tages-Spanne:
$0.61
$0.64
1-Wochen-Bereich:
$0.551
$0.64
52-Wochen-Spanne:
$0.492
$1.9198
Longeveron Inc Stock (LGVN) Company Profile
Firmenname
Longeveron Inc
Sektor
Branche
Telefon
305-302-7158
Adresse
1951 NW 7TH AVENUE, MIAMI
Vergleichen Sie LGVN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LGVN
Longeveron Inc
|
0.6233 | 13.42M | 1.89M | -17.92M | -15.62M | -6.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Longeveron Inc Stock (LGVN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-06 | Eingeleitet | ROTH MKM | Buy |
Longeveron Inc Aktie (LGVN) Neueste Nachrichten
Can Longeveron Inc. stock attract ESG capital inflowsJuly 2025 Technicals & Consistent Profit Trade Alerts - ulpravda.ru
Is Longeveron Inc. stock positioned for long term growthEarnings Growth Report & Daily Price Action Insights - ulpravda.ru
Why Longeveron Inc. stock is considered a top pickJuly 2025 Volume & Consistent Return Strategy Ideas - ulpravda.ru
Will Longeveron Inc. stock continue upward momentumQuarterly Trade Review & Technical Pattern Alert System - ulpravda.ru
Is Longeveron Inc. stock a top momentum play2025 Market Overview & Long-Term Investment Growth Plans - ulpravda.ru
Rockford Register Star: Local News, Politics & Sports in Rockford, IL - FinancialContent
Longeveron Inc.Class A Common stock (NQ: LGVN - FinancialContent
Longeveron Shares Jump as FDA Clears Phase 2 Trial for Pediatric Heart Therapy - MSN
Longeveron, Selected as a StartUp Health Alzheimer’s Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026 - marketscreener.com
Alzheimer’s ‘moonshot’ network taps Longeveron to join 2026 founder summit - Stock Titan
Longeveron (NASDAQ:LGVN) Stock Price Down 3.2% – What’s Next? - Defense World
Will Longeveron Inc. stock attract more institutional investors2025 Market WrapUp & Weekly High Conviction Trade Ideas - Улправда
Is Longeveron Stock Built to Withstand More Downside? - Trefis
Comparing Longeveron (NASDAQ:LGVN) & Senti Biosciences (NASDAQ:SNTI) - Defense World
What drives Longeveron Inc stock priceDouble Top/Bottom Patterns & Trusted Financial Advisors at No Cost - earlytimes.in
Longeveron Earnings Notes - Trefis
Is Longeveron Inc. stock a good choice for value investorsNew Guidance & Verified Stock Trade Ideas - Улправда
What risks investors should watch in Longeveron Inc. stockPortfolio Return Summary & Comprehensive Market Scan Reports - DonanımHaber
Why Longeveron Inc. stock remains on watchlists2025 Valuation Update & Technical Confirmation Trade Alerts - DonanımHaber
Is Longeveron Inc. stock a buy in volatile marketsEarnings Trend Report & Precise Swing Trade Alerts - ulpravda.ru
What technical signals suggest for Longeveron Inc. stockEarnings Summary Report & Fast Moving Stock Trade Plans - Улправда
Longeveron receives patent for stem cell therapy targeting female sexual dysfunction - Investing.com Canada
Longeveron granted U.S. patent for method of treating female sexual dysfunction - marketscreener.com
Longeveron receives patent for stem cell therapy targeting female sexual dysfunction By Investing.com - Investing.com South Africa
Longeveron Granted U.S. Patent for Method of Treating Female Sexual Dysfunction Using its Proprietary Stem Cell Therapy - The Manila Times
Block Trades: What risks investors should watch in Longeveron Inc stockRate Cut & Free High Return Stock Watch Alerts - moha.gov.vn
Beyond Weight Loss: The "Cellular Reset" That Could Create the Next Biotech Supercycle - The Globe and Mail
Longeveron granted Canadian patent covering laromestrocel administration - MSN
Longeveron launches offering of up to 11.8M shares via warrants and stock units - MSN
Prepare Yourself for Liftoff: Longeveron Inc (LGVN) - Setenews
With Longeveron Stock Sliding, Have You Assessed The Risk? - Trefis
Update Recap: Can MCK stock sustain institutional flowsWatch List & Free Weekly Watchlist of Top Performers - BỘ NỘI VỤ
Longeveron executives to speak at CVCT Forum on cell therapy trials - Investing.com Nigeria
Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global CardioVascular Clinical Trialists (CVCT) Forum - The Manila Times
Longeveron (NASDAQ: LGVN) CSO, CMO to Join CVCT Forum Panels on Cell Therapy Trials - Stock Titan
Can Longeveron Inc. stock continue upward trendWeekly Trend Recap & Fast Entry Momentum Alerts - Newser
Longeveron (LGVN) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Longeveron receives Canadian patent for stem cell therapy By Investing.com - Investing.com Nigeria
Perhaps timely catching Longeveron Inc (LGVN) would be a good idea - Setenews
Longeveron receives Canadian patent for stem cell therapy - Investing.com
Longeveron granted Canadian patent for method of using stem cells to treat non-ischemic dilated cardiomyopathy - MarketScreener
Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-related Frailty in Patients with Inflammaging - The Manila Times
Longeveron (NASDAQ: LGVN) gets Canada patent on LOMECEL-B for frailty and NIDCM - Stock Titan
Longeveron’s stem cell therapy shows reduced neuroinflammation in AD trial By Investing.com - Investing.com South Africa
Longeveron to present MRI biomarker data in Alzheimer’s at CTAD 2025 - TipRanks
Longeveron New MRI Biomarker Data Linking Neuroinflammation to Clinical Outcomes in Patients with Mild Alzheimer’s Disease Presented at the Clinical Trials on Alzheimer’s Disease Conference (CTAD 2025) - The Manila Times
Longeveron (NASDAQ: LGVN) sees MRI inflammation drop in 13 of 14 brain regions at week 39 - Stock Titan
Finanzdaten der Longeveron Inc-Aktie (LGVN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):